CLINICAL TRIALS PROFILE FOR GAMMAGARD LIQUID
✉ Email this page to a colleague
All Clinical Trials for GAMMAGARD LIQUID
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01736579 ↗ | Long-Term Study of IGIV, 10% in Alzheimer´s Disease | Terminated | Baxalta now part of Shire | Phase 3 | 2012-11-29 | The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor. |
| NCT01736579 ↗ | Long-Term Study of IGIV, 10% in Alzheimer´s Disease | Terminated | Baxalta US Inc. | Phase 3 | 2012-11-29 | The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor. |
| NCT02123615 ↗ | ASIS for GAMMAGARD in Primary Immunodeficiency | Unknown status | ASIS Corporation | Phase 1/Phase 2 | 2016-01-01 | ASIS Corporation (ASIS) has developed the only automatic injection system for delivery of injectable products to it's optimum/right spot, just outside of the fascia, which exists subdermally (between the skin and muscle). Bloodless basically implies longer lasting medicinal effects, and minimal side effects - advantages that reflect the NIH mission of enhancing health, lengthening life, and reducing the burdens of illness and disability. ASIS device is stabilized on the surface of the skin with negative pressure and emits an electrical current to create a bloodless cavity subdermally. ASIS device correctly, automatically, and consistently delivers therapeutic agents, yet requiring little skill of a practitioner - providing the steady and safe infusion into subdermal bloodless space of virtually any injectable product in addition to Botox, including GAMMAGARD LIQUID, Enbrel, Insulin, and Fillers, etc. According to the FDA, "This innovation will have major impact on the healthcare industry." |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GAMMAGARD LIQUID
Condition Name
Clinical Trial Locations for GAMMAGARD LIQUID
Trials by Country
Clinical Trial Progress for GAMMAGARD LIQUID
Clinical Trial Phase
Clinical Trial Sponsors for GAMMAGARD LIQUID
Sponsor Name
